Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients

Zehir, Ahmet, Benayed, Ryma, Shah, Ronak H, Syed, Aijazuddin, Middha, Sumit, Kim, Hyunjae R, Srinivasan, Preethi, Gao, Jianjiong +92 more·2017·Nature Medicine
DOI 10.1038/nm.4333

Cited by (1,010)

Items 901–1,000 of 1,010

  1. Pharmacoproteomics Identifies Kinase Pathways that Drive the Epithelial-Mesenchymal Transition and Drug Resistance in Hepatocellular Carcinoma
    Martin G. Golkowski, Ho-Tak Lau, Marina Chan, Heidi L. Kenerson, Venkata Narayana Vidadala, Anna Shoemaker, Dustin J. Maly, Raymond S. W. Yeung, Taranjit S. Gujral, Shao‐En Ong · 2020 · Cell Systems
  2. The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence
    Roy Rabbie, Peter M. Ferguson, Kim Wong, Dominique‐Laurent Couturier, Una Moran, Clinton P. Turner, Patrick O. Emanuel, Kerstin Haas, Jodi M. Saunus, Morgan R. Davidson et al. · 2020 · British Journal of Cancer
  3. Phase I Basket Study of Taselisib, an Isoform-Selective PI3K Inhibitor, in Patients with PIK3CA -Mutant Cancers
    Komal L. Jhaveri, Matthew T. Chang, Dejan Juric, Cristina Saura, Valentina Gambardella, Anton Melnyk, Manish R. Patel, Vincent Ribrag, Cynthia X. Ma, Raid M. Aljumaily et al. · 2020 · Clinical Cancer Research
  4. Targeting the De Novo Purine Synthesis Pathway Through Adenylosuccinate Lyase Depletion Impairs Liver Cancer Growth by Perturbing Mitochondrial Function
    Tingting Jiang, Francisco J. Sánchez Rivera, Yadira M. Soto‐Feliciano, Qiyuan Yang, Chun‐Qing Song, Arjun Bhuatkar, Cole M. Haynes, Michael T. Hemann, Wen Xue · 2020 · Hepatology
  5. Advances in anti-BRAF therapies for lung cancer
    Giandomenico Roviello, Alberto D’Angelo, Marianna Sirico, Matteo Pittacolo, Felipe Umpierre Conter, Navid Sobhani · 2021 · Investigational New Drugs
  6. KRAS G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma
    Gregory D. Jones, Raul Caso, Kay See Tan, Brooke Mastrogiacomo, Francisco Sánchez-Vega, Yuan Liu, James G. Connolly, Yonina R. Murciano‐Goroff, Matthew Joseph Bott, Prasad S. Adusumilli et al. · 2021 · Clinical Cancer Research
  7. Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.
    A. Stenzinger, A. Edsjö, C. Ploeger, Mikaela Friedman, S. Fröhling, V. Wirta, T. Seufferlein, J. Botling, J. Duyster, Michael Akhras et al. · 2021 · Seminars in Cancer Biology
  8. Expanding the spectrum of thyroid carcinoma with somatic DICER1 mutation: a survey of 829 thyroid carcinomas using MSK-IMPACT next-generation sequencing platform
    Charles A. Ghossein, Snjezana Doğan, Nada A. Farhat, Iñigo Landa, Bin Xu · 2021 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  9. SRDFM: Siamese Response Deep Factorization Machine to improve anti-cancer drug recommendation
    Ran Su, Yixuan Huang, Degan Zhang, Guobao Xiao, Leyi Wei · 2021 · Briefings in Bioinformatics
  10. Advancing molecular tumour boards: highly needed to maximise the impact of precision medicine
    Joris van de Haar, Louisa Rose Hoes, Emile E. Voest · 2019 · ESMO Open
  11. Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers
    Natalie Y.L. Ngoi, Tin‐Yun Tang, Catia Fava Gaspar, Dean C. Pavlick, Gregory M. Buchold, Emma L. Scholefield, Vamsi Parimi, Richard S.P. Huang, Tyler Janovitz, Natalie A. Danziger et al. · 2024 · The Oncologist
  12. 2016 New Horizons Lecture: Beyond Imaging—Radiology of Tomorrow
    Hedvig Hricak · 2018 · Radiology
  13. Anaplastic Lymphoma Kinase Mutation ( ALK F1174C) in Small Cell Carcinoma of the Prostate and Molecular Response to Alectinib
    Benedito A. Carneiro, Sahithi Pamarthy, Ami N. Shah, Vinay Sagar, Kenji Unno, Huiying Han, Ximing J. Yang, Rubens Barros Costa, Rebecca J. Nagy, Richard Burnham Lanman et al. · 2018 · Clinical Cancer Research
  14. The impact of phosphatases on proliferative and survival signaling in cancer
    Goutham Narla, Jaya Sangodkar, Christopher B. Ryder · 2018 · Cellular and Molecular Life Sciences
  15. Oncogenic c-terminal cyclin D1 (CCND1) mutations are enriched in endometrioid endometrial adenocarcinomas
    Jia L. Xu, Douglas I. Lin · 2018 · PLoS ONE
  16. A scalable solution for tumor mutational burden from formalin-fixed, paraffin-embedded samples using the Oncomine Tumor Mutation Load Assay
    Ruchi Chaudhary, Luca Quagliata, Philip M. Jermann, Ilaria Alborelli, Dinesh Cyanam, Vinay Mittal, Warren Tom, Janice K. Au-Young, Seth E. Sadis, Fiona C. L. Hyland · 2018 · Translational Lung Cancer Research
  17. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues
    Kenji Amemiya, Yosuke Hirotsu, Toshio Oyama, Masao Omata · 2018 · Clinica Chimica Acta
  18. Biomarkers: What Role Do They Play (If Any) for Diagnosis, Prognosis and Tumor Response Prediction for Hepatocellular Carcinoma?
    James J. Harding, Danny N. Khalil, Ghassan K. Abou‐Alfa · 2019 · Digestive Diseases and Sciences
  19. Genetic and histologic spatiotemporal evolution of recurrent, multifocal, multicentric and metastatic glioblastoma
    Maria-Magdalena Georgescu, Adriana Olar · 2020 · Acta Neuropathologica Communications
  20. Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in Real-World Clinical Practice
    Aditi Puri Singh, Elaine Shum, Lakshmi N. Rajdev, Haiying Cheng, Sanjay Goel, Roman Perez-Soler, Balázs Halmos · 2020 · Cancers
  21. BAP1 is a haploinsufficient tumor suppressor linking chronic pancreatitis to pancreatic cancer in mice
    Stephanie Perkail, Jaclyn Andricovich, Kai Yan, Alexandros Tzatsos · 2020 · Nature Communications
  22. The emerging role of antibody-drug conjugates in urothelial carcinoma
    Michael William Lattanzi, Jonathan E. Rosenberg · 2020 · Expert Review of Anticancer Therapy
  23. Molecular and clinicopathological features of appendiceal mucinous neoplasms
    Yuka Yanai, Tsuyoshi Saito, Takuo Hayashi, Yoichi Akazawa, Noboru Yatagai, Sho Tsuyama, Shigeki Tomita, Shu Hirai, Kanako Ogura, Toshiharu Matsumoto et al. · 2020 · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin
  24. Direct plasmonic detection of circulating RAS mutated DNA in colorectal cancer patients
    Roberta D’Agata, Noemi Bellassai, Matteo Allegretti, Andrea Rozzi, Saša Korom, Alex Manicardi, Elisa Melucci, Edoardo O. Pescarmona, Roberto Corradini, Patrizio Giacomini et al. · 2020 · Biosensors and Bioelectronics
  25. Dual inhibition of DNA-PK and DNA polymerase theta overcomes radiation resistance induced by p53 deficiency
    Rashmi J. Kumar, Hui Xiao Chao, Dennis A. Simpson, Wanjuan Feng, Min-Guk Cho, Victoria Roberts, Aurora R Sullivan, Sonam Shah, Anne‐Sophie Wozny, Katerina D. Fagan‐Solis et al. · 2020 · NAR Cancer
  26. Mutations in the RAS/MAPK Pathway Drive Replication Repair–Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition
    Brittany B. Campbell, Melissa A. Galati, Simone C. Stone, Alexandra N. Riemenschneider, Melissa Edwards, Sumedha Sudhaman, Robert Siddaway, Martin Komosa, Nuno M. Nunes, Liana Figueiredo Nobre et al. · 2021 · Cancer Discovery
  27. PTEN mutations predict benefit from tumor treating fields (TTFields) therapy in patients with recurrent glioblastoma
    Antonio Dono, Sonali Mitra, Mauli Shah, Takeshi Takayasu, Jay‐Jiguang Zhu, Nitin Tandon, Chirag B. Patel, Yoshua Esquenazi, Leomar Y. Ballester · 2021 · Journal of Neuro-Oncology
  28. Prognostic and immunological role of CD36: A pan-cancer analysis
    Yongjian Chen, Weixin Liao, Shaozhuo Huang, Yunfang Yu, Jing‐Yun Wen, Jie Chen, Dagui Lin, Xiangyuan Wu, Nan Jiang, Xing Li · 2021 · Journal of Cancer
  29. TSC2-mutant uterine sarcomas with JAZF1-SUZ12 fusions demonstrate hybrid features of endometrial stromal sarcoma and PEComa and are responsive to mTOR inhibition
    Sarah Chiang, Varshini Vasudevaraja, Jonathan Serrano, Colin J.R. Stewart, Esther Oliva, Amir Momeni Boroujeni, Achim A. Jungbluth, Arnaud Da Cruz Paula, Edaise M. da Silva, Britta Weigelt et al. · 2021 · Modern Pathology
  30. Trends in Diagnosis and Treatment of Metastatic Cancer in the United States
    Eric J. Lehrer, Kelsey C. Stoltzfus, Brianna M. Jones, Niraj Jaysukh Gusani, Vonn Walter, Ming Wang, Daniel Michael Trifiletti, Shankar Siva, Alexander V. Louie, Nicholas George Zaorsky · 2021 · American Journal of Clinical Oncology
  31. LTF Regulates the Immune Microenvironment of Prostate Cancer Through JAK/STAT3 Pathway
    Qi Zhao, Yingying Cheng, Ying Xiong · 2021 · Frontiers in Oncology
  32. EGFR suppresses p53 function by promoting p53 binding to DNA-PKcs: a noncanonical regulatory axis between EGFR and wild-type p53 in glioblastoma
    Jie Ding, Xiaolong Li, Sabbir Khan, Chen Zhang, Feng Gao, Shayak Sen, Amanda R. Wasylishen, Yang Zhao, Guillermina Lozano, Dimpy Koul et al. · 2022 · Neuro-Oncology
  33. Molecular profiling and target actionability for precision medicine in neuroendocrine neoplasms: real-world data
    Alice Boilève, Matthieu Faron, Sarah Fodil-Cherif, Arnaud Bayle, Livia Lamartina, David Planchard, Lambros Tselikas, Christina Kanaan, Jean‐Yves Scoazec, Michel Pierre Ducreux et al. · 2023 · European Journal of Cancer
  34. Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer
    Lucile Pabst, Sébastien Lopes, Basil Bertrand, Quentin Creusot, Maria Kotovskaya, Erwan Pencreach, Michèle Beau‐Faller, Céline Mascaux · 2023 · International Journal of Molecular Sciences
  35. Practice-Level Variation in Molecular Testing and Use of Targeted Therapy for Patients With Non–Small Cell Lung Cancer and Colorectal Cancer
    Thomas J. Roberts, Kenneth L. Kehl, Gabriel A. Brooks, Lynette Marie Sholl, Alexi A. Wright, Mary Beth Landrum, Nancy Lynn Keating · 2023 · JAMA Network Open
  36. Reactivation of telomerase reverse transcriptase expression in cancer: the role of TERT promoter mutations
    Maria Lina Tornesello, Andrea Cerasuolo, Noemy Starita, Sara Amiranda, Patrizia Bonelli, Franca Maria Tuccillo, Franco M. Buonaguro, Luigi Buonaguro, Anna Lucia Tornesello · 2023 · Frontiers in Cell and Developmental Biology
  37. HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicity
    David Bassan, Leehee Weinberger, Jason Yi, Tanya Kim, Michael R. Weist, Gregor B. Adams, Orit Foord, Neta Chaim, Sarit Tabak, Nir Bujanover et al. · 2023 · Journal for ImmunoTherapy of Cancer
  38. CDK4/6i-treated HR+/HER2- breast cancer tumors show higher ESR1 mutation prevalence and more altered genomic landscape
    Nayan Chaudhary, Alejandro Martinez Chibly, Ann Collier, Jorge Martinalbo, Pablo Perez-Moreno, Heather M. Moore, Patricia Luhn, Ciara Metcalfe, Marc A. Hafner · 2024 · npj Breast Cancer
  39. Building a translational cancer dependency map for The Cancer Genome Atlas
    Xu Shi, Christos Gekas, Daniel Verduzco, Sakina M. Petiwala, Cynthia T. Jeffries, Charles Lu, Erin Murphy, Tifani Anton, Andy H. Vo, Zhiguang Xiao et al. · 2024 · Nature Cancer
  40. DNA liquid biopsy-based prediction of cancer-associated venous thromboembolism
    Justin Jee, Angela Rose Brannon, Rohan Kumar Singh, Andriy Derkach, Christopher John Fong, Adrian V. Lee, Lauren Gray, Karl Pichotta, Anisha Luthra, Monica S. Diosdado et al. · 2024 · Nature Medicine
  41. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma
    Maria F. Becerra, Ed Reznik, Almedina Redzematovic, Daniel M. Tennenbaum, Mahyar Y. Kashan, Mazyar Ghanaat, Jozefina Casuscelli, Brandon J. Manley, Philip Jonsson, Renzo G. DiNatale et al. · 2017 · European Urology Focus
  42. GNAQ Mutations in Diffuse and Solitary Choroidal Hemangiomas
    Jasmine H. Francis, Tatyana Milman, Hans E. Grossniklaus, Daniel Myron Albert, Robert Folberg, Gregory M. Levitin, Sarah E. Coupland, Federica Catalanotti, David Z. Rabady, Cyriac Kandoth et al. · 2018 · Ophthalmology
  43. ESR1 mutations in metastatic lobular breast cancer patients
    Christine Desmedt, Julien Pingitore, Françoise Rothé, Caterina Marchiò, Florian Clatot, Ghizlane Rouas, François Richard, François Bertucci, Odette Mariani, Christine Galant et al. · 2019 · npj Breast Cancer
  44. Immunotherapy in Gynecologic Cancers: What We Know Now and Where We Are Headed
    Kimberly L. Levinson, Oliver Dorigo, Krista M. Rubin, Kathleen N. Moore · 2019 · American Society of Clinical Oncology Educational Book
  45. The prognostic value of tumor mutation burden in EGFR-mutant advanced lung adenocarcinoma, an analysis based on cBioPortal data base
    Xiao‐Dong Jiao, Xi He, Bao‐Dong Qin, Ke Liu, Ying Wu, Jun Liu, Ting Hou, Yuan‐Sheng Zang · 2019 · Journal of Thoracic Disease
  46. Clinical and molecular characterization of primary sclerosing epithelioid fibrosarcoma of bone and review of the literature
    Yusuke Tsuda, Brendan Craig Dickson, Sarah Dry, Noah C. Federman, Albert J.H. Suurmeijer, David Michael Swanson, Yun‐Shao Sung, Lei Zhang, John H. Healey, Cristina R. Antonescu · 2019 · Genes Chromosomes and Cancer
  47. Lung-only melanoma: UV mutational signature supports origin from occult cutaneous primaries and argues against the concept of primary pulmonary melanoma
    Chen Yang, Francisco Sánchez-Vega, Jason C. Chang, Walid Khaled Chatila, Alexander Noor Shoushtari, Marc Ladanyi, William David Travis, Klaus Johannes BUSAM, Natasha Rekhtman · 2020 · Modern Pathology
  48. Discovering functional evolutionary dependencies in human cancers
    Marco Mina, Arvind Iyer, Daniele Tavernari, Franck Raynaud, Giovanni Ciriello · 2020 · Nature Genetics
  49. Targeting Germline- and Tumor-Associated Nucleotide Excision Repair Defects in Cancer
    Sabine Topka, Zoe Steinsnyder, Vignesh Ravichandran, Kaitlyn A. Tkachuk, Yelena M. Kemel, Chaitanya Bandlamudi, Mogens Winkel Madsen, Helena F. Furberg, Ouathek Ouerfelli, Charles M. Rudin et al. · 2020 · Clinical Cancer Research
  50. Comprehensive molecular profiling broadens treatment options for breast cancer patients
    Hitomi Kawaji, Makoto Kubo, Nami Yamashita, Hidetaka Yamamoto, Masaya Kai, Atsuko Kajihara, Mai Yamada, Kanako Kurata, Kazuhisa Kaneshiro, Yurina Harada et al. · 2020 · Cancer Medicine
  51. The genomic and immunologic profiles of pure pulmonary sarcomatoid carcinoma in Chinese patients
    Fei Zhou, Yan Huang, Weijing Cai, Jin Li, Chunxia Su, Shengxiang Ren, Chunyan Wu, Caicun Zhou · 2021 · Lung Cancer
  52. Genomic alterations in PIK3CA-mutated breast cancer result in mTORC1 activation and limit the sensitivity to PI3Kα inhibitors
    Yan-Yan Cai, Guotai Xu, Fan Wu, Flavia Michelini, Carmen Chan, X. Qu, P. Selenica, Erik M. Ladewig, P. Castel, Yuan-Ming Cheng et al. · 2021 · Cancer Research
  53. IDH2 R172 Mutations Across Poorly Differentiated Sinonasal Tract Malignancies
    Stefanie Glöß, Philipp Sebastian Jurmeister, Anne Thieme, Simone Schmid, Wei Y. Cai, Rene Serrette, Sven Perner, Julika Ribbat‐Idel, Axel Pagenstecher, Hendrik Bläker et al. · 2021 · The American Journal of Surgical Pathology
  54. Pan‐cancer analysis of prognostic metastatic phenotypes
    Nicholas George Zaorsky, Xi Wang, Sara M. Garrett, Eric J. Lehrer, Christine S. Lin, David J. DeGraff, Daniel Eidelberg Spratt, Daniel Michael Trifiletti, Amar Upadhyaya Kishan, Timothy Norman Showalter et al. · 2021 · International Journal of Cancer
  55. Inhibition of nonsense-mediated decay rescues p53β/γ isoform expression and activates the p53 pathway in MDM2-overexpressing and select p53-mutant cancers
    Jayanthi P. Gudikote, Tina Cascone, Alissa Poteete, Piyada Sitthideatphaiboon, Qiuyu Wu, Naoto Morikawa, Fahao Zhang, Shaohua Peng, Pan Tong, Lerong Li et al. · 2021 · Journal of Biological Chemistry
  56. Molecular characterization of uterine and ovarian tumors with mixed epithelial and germ cell features confirms frequent somatic derivation
    Stephanie L. Skala, Chia‐Jen Liu, Aaron M. Udager, Andrew P. Sciallis · 2020 · Modern Pathology
  57. Functional Drug Screening in the Era of Precision Medicine
    Giulia C. Napoli, William Douglas Figg, Cindy H. Chau · 2022 · Frontiers in Medicine
  58. Integrated molecular and clinical analysis of BRAF-mutant glioma in adults
    Karisa C. Schreck, Pinky Langat, Varun M. Bhave, Taibo Li, E. L. Woodward, Christine A. Pratilas, Charles G. Eberhart, Wenya Linda Bi · 2023 · npj Precision Oncology
  59. Reliable interpretability of biology-inspired deep neural networks
    2023
  60. Microsatellite Instability and Mismatch Repair Deficiency Define a Distinct Subset of Lung Cancers Characterized by Smoking Exposure, High Tumor Mutational Burden, and Recurrent Somatic MLH1 Inactivation
    Soo‐Ryum Yang, Erika Gedvilaite, Ryan N. Ptashkin, Jason C. Chang, John Ziegler, Douglas A. Mata, Liliana B. Villafania, Khédoudja Nafa, Jaclyn Frances Hechtman, Ryma Benayed et al. · 2023 · Journal of Thoracic Oncology
  61. Tumor sequencing of African ancestry reveals differences in clinically relevant alterations across common cancers
    Evelyn Mawunyo Jiagge, Dexter X. Jin, Justin Y. Newberg, Tomin E. Perea-Chamblee, Kelly R. Pekala, Christopher John Fong, Michele Waters, David Ma, Yvonne Dei‐Adomakoh, Gilles Erb et al. · 2023 · Cancer Cell
  62. Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities
    Chao Chen, Cai‐Jin Lin, Yu‐Chen Pei, Ding Ma, Li Liao, Si‐Yuan Li, Lei Fan, Gen‐Hong Di, Song‐Yang Wu, Xiyu Liu et al. · 2023 · Cell Discovery
  63. Classification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets
    Kyle Ellrott, Christopher K. Wong, Christina S. F. Yau, Mauro A.A. Castro, Jordan Lee, Brian Karlberg, Jasleen Grewal, Vincenzo Lagani, Bahar Tercan, Verena Friedl et al. · 2025 · Cancer Cell
  64. Rates ofERBB2Alterations across Melanoma Subtypes and a Complete Response to Trastuzumab Emtansine in anERBB2-Amplified Acral Melanoma
    Lee S. Gottesdiener, Shannon O'Connor, Klaus Johannes BUSAM, Helen H. Won, David B. Solit, David Michael Hyman, Alexander Noor Shoushtari · 2018 · Clinical Cancer Research
  65. Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer
    Ahmed Basudan, Nolan Priedigkeit, Ryan James Hartmaier, Ethan S. Sokol, Amir Bahreini, Rebecca Jean Watters, Michelle M. Boisen, Rohit Bhargava, Kurt Richard Weiss, Maria Margarete Karsten et al. · 2018 · Molecular Cancer Research
  66. Targeted next-generation sequencing of well-differentiated rectal, gastric, and appendiceal neuroendocrine tumors to identify potential targets
    Ha Young Park, Mi Jung Kwon, Ho Suk Kang, Yun Joong Kim, Nan Young Kim, Min Jeong Kim, Kyueng‐Whan Min, Kyung Chan Choi, Eun Sook Nam, Seong Jin Cho et al. · 2019 · Human Pathology
  67. Targeted mutation detection in breast cancer using MammaSeq™
    Nicholas G. Smith, Rekha Gyanchandani, Osama Shiraz Shah, Grzegorz T. Gurda, Peter C. Lucas, Ryan James Hartmaier, Adam Brufsky, Shannon Puhalla, Amir Bahreini, Karthik Joshua Kota et al. · 2019 · Breast Cancer Research
  68. Genomic Alteration Burden in Advanced Prostate Cancer and Therapeutic Implications
    Matthew J. Ryan, Rohit Bose · 2019 · Frontiers in Oncology
  69. Supportive roles of brain macrophages in CNS metastases and assessment of new approaches targeting their functions
    Hua You, Szymon Baluszek, Bozena Kaminska · 2020 · Theranostics
  70. Discovery through clinical sequencing in oncology
    Mark T.A. Donoghue, Alison M. Schram, David Michael Hyman, Barry S. Taylor · 2020 · Nature Cancer
  71. Cyclin Pathway Genomic Alterations Across 190,247 Solid Tumors: Leveraging Large-Scale Data to Inform Therapeutic Directions
    Denis L. Fontes Jardim, Sherri Z. Millis, Jeffrey S. Ross, Michelle Sue-Ann Woo, Siraj Mahamed Ali, Razelle Kurzrock · 2020 · The Oncologist
  72. Pan-cancer identification of clinically relevant genomic subtypes using outcome-weighted integrative clustering
    Arshi Arora, Adam B. Olshen, Venkatraman Seshan, Ronglai Shen · 2020 · Genome Medicine
  73. Machine learning of genomic features in organotropic metastases stratifies progression risk of primary tumors
    Biaobin Jiang, Quanhua Mu, Fufang Qiu, Xuefeng Li, Weiqi Xu, Jun Yu, Weilun Fu, Yong Bao Cao, Jiguang Wang · 2021 · Nature Communications
  74. Benchmarking HLA genotyping and clarifying HLA impact on survival in tumor immunotherapy
    Xiangyong Li, Chi Zhou, Ke Chen, Bingding Huang, Qi Liu, Hao Ye · 2021 · Molecular Oncology
  75. Growth Hormone/Insulin Growth Factor Axis in Sex Steroid Associated Disorders and Related Cancers
    Rachel Bleach, Mark Sherlock, Michael O’Reilly, Marie McIlroy · 2021 · Frontiers in Cell and Developmental Biology
  76. Optimizing the diagnosis and management of ductal prostate cancer
    Weranja K. B. Ranasinghe, Daniel D. Shapiro, Miao Zhang, Tharakeswara Kumar Bathala, Nora Maria Navone, Timothy C. Thompson, Bradley McIntosh Broom, Ana M. Aparicio, Shi‐Ming Tu, Chad Z. Tang et al. · 2021 · Nature Reviews Urology
  77. Precision Medicine for Hepatocellular Carcinoma: Clinical Perspective
    Danijel A. Galun, Dragana Danilo Mijac, Aleksandar Filipović, Aleksandar Bogdanović, Marko Zivanovic, Dragan Mašulović · 2022 · Journal of Personalized Medicine
  78. AKT mutant allele-specific activation dictates pharmacologic sensitivities
    Tripti Shrestha-Bhattarai, Tambudzai Shamu, Alexander N. Gorelick, Matthew T. Chang, Debyani Chakravarty, Elena I. Gavrila, Mark T.A. Donoghue, JianJong Gao, Swati Patel, Sizhi Paul Gao et al. · 2022 · Nature Communications
  79. Somatic ARID1A mutation stratifies patients with gastric cancer to PD-1 blockade and adjuvant chemotherapy
    Yun Gu, Puran Zhang, Jieti Wang, Chao Lin, Hao Liu, He Li, Hongyong He, Ruochen Li, Heng Zhang, Weijuan Zhang · 2022 · Cancer Immunology Immunotherapy
  80. Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2
    Rengyun Liu, Jie Tan, Xiaopei Shen, Ke Jiang, Chaoqun Wang, Guangwu Zhu, Mingzhao Xing · 2021 · Proceedings of the National Academy of Sciences
  81. Neoplasia risk in patients with Lynch syndrome treated with immune checkpoint blockade
    Emily C. Harrold, Michael Bonner Foote, Benoı̂t Rousseau, Henry S. Walch, Yelena M. Kemel, Allison L. Richards, Fergus Keane, Andrea Cercek, Rona D. Yaeger, Dana E. Rathkopf et al. · 2023 · Nature Medicine
  82. Enhanced clinical assessment of hematologic malignancies through routine paired tumor and normal sequencing
    Ryan N. Ptashkin, Mark David Ewalt, Gowtham Jayakumaran, Iwona J Kiecka, Anita S. Bowman, JinJuan Yao, Jacklyn Casanova, Yun-Te David Lin, Kseniya Petrova‐Drus, Abhinita S. Mohanty et al. · 2023 · Nature Communications
  83. Dabrafenib and trametinib administration in patients with BRAF V600E/R or non-V600 BRAF mutated advanced solid tumours (BELIEVE, NCCH1901): a multicentre, open-label, and single-arm phase II trial
    Tatsunori Shimoi, Kuniko Sunami, Makoto Tahara, Satoshi Nishiwaki, Shota Tanaka, Eishi Baba, Masashi Kanai, Ichiro Kinoshita, Hidekazu Shirota, Hideyuki Hayashi et al. · 2024 · EClinicalMedicine
  84. Analytical Validation of Clinical Whole-Genome and Transcriptome Sequencing of Patient-Derived Tumors for Reporting Targetable Variants in Cancer
    K. Wrzeszczynski, Vanessa Felice, A. Abhyankar, Lukasz Kozon, Heather Geiger, Dina Manaa, Ferrah London, Dino Robinson, Xiaolan Fang, D. Lin et al. · 2018 · Journal of Molecular Diagnostics
  85. Brain metastasis in epithelial ovarian cancer by BRCA1/2 mutation status
    Marina Stasenko, Paulina Cybulska, Noah Z. Feit, Vicky Makker, Jason A. Konner, Roisin Eilish O'Cearbhaill, Kaled M. Alektiar, Kathryn P. Beal, Ginger J. Gardner, Kara Long Roche et al. · 2019 · Gynecologic Oncology
  86. A P53-Independent DNA Damage Response Suppresses Oncogenic Proliferation and Genome Instability
    Katerina D. Fagan‐Solis, Dennis A. Simpson, Rashmi J. Kumar, Luciano Gastón Martelotto, Lisle E. Mose, Naim U. Rashid, Alice Y. Ho, Simon N. Powell, Yuetao Wen, Joel S. Parker et al. · 2020 · Cell Reports
  87. Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population
    Anh-Thu Huynh Dang, Vu-Uyen Tran, Thanh-Truong Tran, Hong-Anh Thi Pham, Dinh-Thong Vu Le, Lam Nguyen, Ngoc Vu Nguyen, Thai-Hoa Thi Nguyen, Chu Van Nguyen, Ha Thu Le et al. · 2020 · Scientific Reports
  88. Comprehensive Analysis of MEN1 Mutations and Their Role in Cancer
    Devi D. Nelakurti, Amrit L. Pappula, Swetha Rajasekaran, Wayne O. Miles, Ruben C. Petreaca · 2020 · Cancers
  89. BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer
    Goldie Y.L. Lui, Reid C. Shaw, Franz X. Schaub, Isabella N. Stork, Kay E. Gurley, Caroline Bridgwater, Robert L. Diaz, Rachele Rosati, Hallie A. Swan, Tan A. Ince et al. · 2020 · EBioMedicine
  90. Association of clock-like mutational signature with immune checkpoint inhibitor outcome in patients with melanoma and NSCLC
    Wei Chong, Zhe Wang, Liang Shang, Shengtao Jia, Jin Liu, Zhen Fang, Fengying Du, Hao Wu, Yang Liu, Yang Chen et al. · 2020 · Molecular Therapy — Nucleic Acids
  91. CTLA4 has a profound impact on the landscape of tumor-infiltrating lymphocytes with a high prognosis value in clear cell renal cell carcinoma (ccRCC)
    Shiyi Liu, Feiyan Wang, Wei Tan, Li Zhang, Fangfang Dai, Yanqing Wang, Yaqi Fan, Mengqin Yuan, Dongyong Yang, Yajing Zheng et al. · 2020 · Cancer Cell International
  92. Immunotherapy in Breast Cancer Patients: A Focus on the Use of the Currently Available Biomarkers in Oncology
    Carmen Criscitiello, Elena Guerini‐Rocco, Giulia Viale, Caterina Fumagalli, Elham Sajjadi, Konstantinos Venetis, Roberto Piciotti, Marco Invernizzi, Umberto Malapelle, Nicola Fusco · 2021 · Anti-Cancer Agents in Medicinal Chemistry
  93. PD-L1P146R is prognostic and a negative predictor of response to immunotherapy in gastric cancer
    Qing Li, Zhiwei Zhou, Lu Jia, Hao Luo, Shunan Wang, Yu Peng, Meng-Sheng Deng, Guanbin Song, Jian-Min Wang, Xi Wei et al. · 2021 · Molecular Therapy
  94. Mutant p53 elicits context-dependent pro-tumorigenic phenotypes
    Jennifer J. McCann, Irina A. Vasilevskaya, Christopher M. McNair, Peter Gallagher, Neermala Poudel Neupane, Renée de Leeuw, Ayesha A. Shafi, Emanuela Dylgjeri, Amy C. Mandigo, Matthew Joseph Schiewer et al. · 2021 · Oncogene
  95. PI3KCA Mutations in Uterine Cervix Carcinoma
    Ioannis A. Voutsadakis · 2021 · Journal of Clinical Medicine
  96. Defining Novel DNA Virus-Tumor Associations and Genomic Correlates Using Prospective Clinical Tumor/Normal Matched Sequencing Data
    Chad Vanderbilt, Anita S. Bowman, Sumit Middha, Kseniya Petrova‐Drus, Yi‐Wei Tang, Xin Chen, Youxiang Wang, Jason C. Chang, Natasha Rekhtman, Klaus Johannes BUSAM et al. · 2022 · Journal of Molecular Diagnostics
  97. Genomic alterations in cholangiocarcinoma: clinical significance and relevance to therapy
    Marianeve Carotenuto, Alessandra Sacco, Laura Forgione, Nicola Normanno · 2022 · Exploration of Targeted Anti-tumor Therapy
  98. Immunotherapy and Microbiota for Targeting of Liver Tumor-Initiating Stem-like Cells
    Keigo Machida, Stanley M. Tahara · 2022 · Cancers
  99. Tumor-immune microenvironment and NRF2 associate with clinical efficacy of PD-1 blockade combined with chemotherapy in lung squamous cell carcinoma
    Jianchun Duan, Yun Zhang, Ran Chen, Liang Liang, Yi Huo, Shun Lü, Jun Zhao, Chunhong Hu, Yuping Sun, Kunyu Yang et al. · 2023 · Cell Reports Medicine
  100. Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapy
    Talal Hilal, Mari Nakazawa, Jacob Hodskins, John Lee Villano, Aju Mathew, Gaurav Goel, Lars M. Wagner, Susanne M. Arnold, Philip A. DeSimone, Lowell Brian Anthony et al. · 2017 · BMC Cancer